2021-01-04,"b""$IPHA Innate pharm's NKp46 NKCEs binds to one or two antigens at the surface of tumor cells, and engage both CD16 and NKp46 activating receptors on NK cells. The co-engagement of NKp46 synergizes with CD16 to induce full NK cell activation and tumor cell lysis. Phase 1 currently."""
2020-12-28,b'$IPHA was analyzed by 2 analysts. The buy consensus is at 80%. So analysts seem to be mildly confident about $IPHA. https://t.co/WW8TZWI9Xy https://t.co/xCn5oxEy5I'
2021-01-07,"b""Rose Above Previous Day's High today: $ICBK $INAQU $IDXG $IHC $CZA $TXRH $AVXL $HEWU $NREF $IMNM $INBKZ $CATC $BMED $IPHA $MJJ $CTDD $HFFG $HLNE $JRSH $IMGN ... https://t.co/TBYRpvrFqi"""
2021-01-07,b'RT @Lybsoo: New INNATE PHARMA\xe2\x80\x99s corporate presentation for $iph $ipha\n\nhttps://t.co/FBOzD2YZUu https://t.co/EEmU2AgDWZ'
2021-01-07,b'RT @Lybsoo: New INNATE PHARMA\xe2\x80\x99s corporate presentation for $iph $ipha\n\nhttps://t.co/FBOzD2YZUu https://t.co/EEmU2AgDWZ'
2021-01-07,b'New INNATE PHARMA\xe2\x80\x99s corporate presentation for $iph $ipha\n\nhttps://t.co/FBOzD2YZUu https://t.co/EEmU2AgDWZ'
2021-01-06,b'RT @Lybsoo: New abstract in coming for INNATE PHARMA ( $ipha ) \xe2\x80\x98s Monalizumab with mFOLFOX6 and Bevacizumab or Cetuximab in MSS-CRC (25 Jan\xe2\x80\xa6'
2021-01-06,b'New abstract in coming for INNATE PHARMA ( $ipha ) \xe2\x80\x98s Monalizumab with mFOLFOX6 and Bevacizumab or Cetuximab in MSS-CRC (25 January)\n\nhttps://t.co/FOz4FFLcqq https://t.co/0BhqGRODYd'
2021-01-06,b'Rose Above 50 DMA today: $NIU $THMO $TDF $HE $ARTNA $CNSL $HTA $MDGS $INDT $JT $IPHA $YVR $BDTX $CSOD $KELYB $SOLN $LARK ... https://t.co/qwiJH6vr1O'
